Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

NCT02948933 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT02948933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Observational
Overall status
Completed
Start date
December 14, 2016
Completion date
December 22, 2022
Enrollment
30,000 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever, dengue hemorrhagic fever